1 |
ClinicalTrials.gov (NCT04553692) Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers. U.S. National Institutes of Health.
|
2 |
Clinical pipeline report, company report or official report of IGM Biosciences.
|
3 |
Clinical pipeline report, company report or official report of Amgen (2009).
|
4 |
National Cancer Institute Drug Dictionary (drug id 528015).
|
5 |
ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
6 |
Clinical pipeline report, company report or official report of Inhibrx.
|
7 |
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
|
8 |
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
|
9 |
National Cancer Institute Drug Dictionary (drug name Tilogotamab).
|
10 |
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
|
11 |
Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.
|
|
|
|
|
|
|